The HER-2/neu story: From oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy

European Journal of Surgical Oncology

Volumn 25, Issue 2, 1999, Pages 111-112

  Mehigan, B J ^a   Kerin, M J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE; RECEPTOR; TAMOXIFEN; VASCULOTROPIN;

BREAST CANCER; CHEMOTHERAPY; CLINICAL TRIAL; DISEASE MARKER; EDITORIAL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; META ANALYSIS; MOLECULAR BIOLOGY; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0032913299     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1998.0611     Document Type: Editorial

References (16)

1. D. Lane The promise of molecular oncology Lancet 351 (Suppl. II) 1998 17 20
2. L. Coussens TL. Yang-Feng YC. Laio Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location withneu oncogene Science 230 1985 1132 1139
3. T. Akiyama C. Sudo H. Ogawara K. Toyoshima T. Yamamoto The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1986 1644 1646
4. r Nature 312 1984 513 516
5. DJ. Slamon GM. Clark SG. Wong WJ. Levin A. Ullrich WL. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER/2neu oncogene Science 235 1987 177 182
6. IL. Andrulis SB. Bull ME. Blackstein D. Sutherland C. Mak S. Sidlofsky neu/erbB-2 amplification identifies a poor prognosis group of women with node-negative breast cancer J Clin Oncol 16 1998 1340 1349
7. A. Evans S. Pinder R. Wilson M. Sibbering D. Poller C. Elston I. Ellis Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings AJR 162 1994 1307 1311
8. S. Paik J. Bryant C. Park erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 1998 1361 1370
9. GM. Clark Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? J Natl Cancer Inst 90 1998 1320 1321
10. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumour cells to tumour necrosis factor Mol Cell Biol 9 1989 1165 1172
11. IM. Harwerth W. Wels J. Schlegel M. Muller NE. Hynes Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth Br J Cancer 68 1993 1140 1145
12. AM. Petit J. Rak MC. Hung Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumour cells in vitro and in vivo: angiogenic implications for signal transduction of solid tumours Am J Pathol 151 1997 1523 1530
13. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
14. HER2 monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 1998 2659 2671
15. TM Proc ASCO abstract 1998 377
16. TM Proc ASCO abstract 1998 376